How much funding has ImmuneID raised?

ImmuneID has raised $70.0M in total funding, most recently a Series A round.

Who are ImmuneID's investors?

ImmuneID's investors include Alta Partners, ARCH Venture Partners, Section 32, Tekla Capital Management, Pitango Growth.

Where is ImmuneID headquartered?

ImmuneID is headquartered in Cambridge, Massachusetts, United States.

What industry is ImmuneID in?

ImmuneID operates in Biotech, Healthcare.

ImmuneID

Cambridge, United States · Founded 2020 · $70.0M raised

Biotech

Healthcare

Headquarters: Cambridge, Massachusetts
Employees: 11–50
Founded: 2020
Business Model: B2B

Website: immuneidrx.com
Total Funding: $70.0M
Last Round: $50.0M Series AJun 2021
Rounds: 2

About

ImmuneID is a precision immunology biopharmaceutical company dedicated to rapidly illuminating and untangling the complexities of the immune system. Using a proprietary platform licensed from Dr. Stephen Elledge's Harvard lab, the company simultaneously identifies and therapeutically targets millions of antibody interactions driving immune diseases. Founded in 2020 by Longwood Fund, ImmuneID is developing therapeutic programs in severe allergy, autoimmunity, and related areas, backed by over $70 million in financing including a $50M Series A.

Summary

ImmuneID is a Biotech company based in Cambridge, United States, founded in 2020. It has raised $70.0M in total across 2 rounds, most recently a $50.0M Series A round in Jun 2021. Investors include Alta Partners, ARCH Venture Partners and Section 32.